Stellar Biotechnologies reported a steep drop in revenues for its fiscal year 2017, but net losses remained flat to the previous year at $5.03 million. Revenue fell from $1.27 million in fiscal 2016 to $228,300 for the year ended Sept. 30. Expenses declined 11.8 percent to $5.45 million, for a net loss of 49 cents…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
